Compare TORM plc (TRMD) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TORM plc vs Vertex Pharmaceuticals Incorporated — how do they compare? TORM plc trades at $40.13 (market cap $4.04B), while Vertex Pharmaceuticals Incorporated trades at $503.25 (market cap $128.16B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 31.7× TORM plc's market cap, and TORM plc pays a 11.36% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold TORM plc for 23 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| TRMD | VRTX | |
|---|---|---|
Market Cap | $4.04B | $128.16B |
Volume | 2,225,810 | 806,603 |
Sector | Industrials | Health |
52-Week High | $41.05 | $557.96 |
52-Week Low | $19.39 | $407.37 |
Typical Hold Time | 23 Days | 120 Days |
Enterprise Value | $4.75B | $122.29B |
Dividend Yield | 11.36% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TRMD trades at $38.92, down 0.33% on the day, with strong profitability metrics including 35.52% net income margin and 26.84% ROE. The stock shows bullish technical signals with moving averages supporting upward momentum, though RSI suggests mild overbought conditions. Recent earnings showed mixed results with Q2 2026 missing expectations, while analyst consensus remains unanimously bullish with 100% buy ratings. The company maintains robust cash flow generation with $710M operating cash flow projected for 2026.
TRMD presents attractive valuation with P/E of 6.4 and EV/EBITDA of 5.11, supported by strong dividend yield from upcoming $2.40 payment. Key risks include spot rate volatility in tanker markets and recent insider selling activity. The fundamental outlook remains positive given projected revenue growth to $1.8B in 2026, though investors should monitor freight rate trends and competitive pressures in the product tanker sector.
Vertex Pharmaceuticals (VRTX) trades at $503.25, showing modest daily gains of 0.16%. The stock faces bearish technical signals with mixed earnings performance, missing Q4 2025 and Q2 2026 EPS estimates but beating Q1 2026. Strong fundamentals include 86% gross margins and 35% net income margins, with revenue projected to grow from $12B to $12.6B in 2026. Recent positive Phase II data for kidney disease drug inaxaplin highlights pipeline progress.
Outlook remains positive with 84% analyst buy ratings and $573 consensus target offering 14% upside. Key risks include reliance on cystic fibrosis franchise and competitive pressures. Earnings consistency and pipeline execution are critical for sustained growth amid current technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TORM plc
TORM plc is one of the world's largest owners and operators of product tankers, specializing in the transportation of refined oil products like gasoline, jet fuel, and diesel. Operating under its integrated 'One TORM' model, the company maintains a modern, wholly-owned fleet of nearly 90 vessels. It is widely recognized by investors for its aggressive variable dividend policy, which returns a significant portion of its cash flow directly to shareholders during periods of high freight rates.
Read more on TRMD →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
